Cap Raise Crucible: Canaccord leads big mining dash for cash
Roundup of 35 ASX capital raisings seeking a combined $687.5m in late August and early September, led by mining deals; Canaccord Genuity topped the broker table and three IPOs floated.
Startup · $7m raised
Every investor coverage indicates participated in a round Prescient Therapeutics raised.
Companies Prescient Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Steven Yatomi-Clarke | Chief Executive | Wholesale Investor |
Stories naming Prescient Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Roundup of 35 ASX capital raisings seeking a combined $687.5m in late August and early September, led by mining deals; Canaccord Genuity topped the broker table and three IPOs floated.
Roundup tallies 35 ASX equity fundraises seeking $687.5 million, mostly miners; Canaccord Genuity led broker mandates with nine deals, while FireFly Metals' $190 million package was the period's largest.
Also The Age Business
Profile of Australian cancer drug developer Prescient Therapeutics, whose basket-trial strategy echoes Loxo Oncology, acquired earlier in 2019 for US$8 billion.